Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship

After updating our health system’s Clostridioides difficile treatment protocols in 2018, we reviewed 104 unique hospital encounters involving fidaxomicin at 10 community hospitals. Half (50%) of regimens were adherent to our guidelines, with infectious diseases (ID) providers were frequently nonadhe...

Full description

Saved in:
Bibliographic Details
Published in:Infection control and hospital epidemiology 2023-02, Vol.44 (2), p.312-314
Main Authors: Khadem, Tina M., Nguyen, M. Hong, Bariola, J. Ryan
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Antibiotics
Antimicrobial agents
Antimicrobial Stewardship
Clinical practice guidelines
Clostridioides
Clostridioides difficile
Clostridium Infections - drug therapy
Concise Communication
Diarrhea
Disease control
Drug therapy
Fidaxomicin - therapeutic use
Hospitals
Hospitals, Community
Humans
Infectious diseases
Patients
Pharmacy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:After updating our health system’s Clostridioides difficile treatment protocols in 2018, we reviewed 104 unique hospital encounters involving fidaxomicin at 10 community hospitals. Half (50%) of regimens were adherent to our guidelines, with infectious diseases (ID) providers were frequently nonadherent. Antimicrobial stewardship programs are important for facilitating best practices, even among ID specialists.
ISSN:0899-823X
1559-6834
DOI:10.1017/ice.2021.456